secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001104659-23-111585
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge
--------------------------------------------------------------------------------

- Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).
- KEYTRUDA sales $6.3B (+17%); GARDASIL/GARDASIL 9 sales $2.6B (+13%).
- Full-year 2023 sales guidance raised to $59.7-$60.2B; Non-GAAP EPS guidance lowered to $1.33-$1.38 due to $5.5B upfront charge from Daiichi Sankyo collaboration.
- Entered collaboration with Daiichi Sankyo for three clinical-stage ADC candidates; upfront payment $5.5B.
- FDA approved KEYTRUDA for perioperative NSCLC; priority review for sotatercept (PDUFA March 26, 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/0001104659-23-111585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/tm2328962d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-111585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer